Neuphoria Therapeutics Inc. (NEUP) FY2026 Annual Balance Sheet

Neuphoria Therapeutics Inc. (NEUP) FY2026 Annual Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets

28,709,016 US dollars

Current assets

21,068,734 US dollars

Non-current assets

7,640,282 US dollars

Liabilities

4,108,994 US dollars

Current liabilities

756,581 US dollars

Non-current liabilities

3,352,413 US dollars

Equity

24,600,022 US dollars

Cash and cash equivalents

19,865,531 US dollars

Accounts receivable, non-trade

813,431 US dollars

Prepaid expenses

389,772 US dollars

Intangible assets, net

4,142,060 US dollars

Goodwill

3,498,222 US dollars

Accounts payable

385,584 US dollars

Accrued expenses and other current liabilities

370,997 US dollars

Accompanying warrant liability

1,971,172 US dollars

Contingent consideration

1,025,301 US dollars

Deferred tax liability

355,940 US dollars

Additional paid in capital, net of subscription receivable

218,461,772 US dollars

Common stock, $0.00001 par value, 5,411,334 and 1,978,460 shares issued and outstanding at June 30, 2026 and 2025, respectively

54 US dollars

Accumulated deficit

negative 191,798,634 US dollars

Accumulated other comprehensive loss, net of tax

negative 2,063,170 US dollars

Chart connections

• Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
• Treasury shares and other negative equity contributions reduce equity.